Miles H. Prince

Melbourne, VIC, AU 
Clinical Trials:Currently Recruiting for 1 Trial
Melbourne, VIC, AU 

Overview

Miles Prince practices practicing medicine in Melbourne, Australia.

His clinical expertise encompasses T-Cell Lymphoma, Mycosis Fungoides, Multiple Myeloma, and Non-Hodgkin Lymphoma.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Melbourne, VIC, Australia
Other Locations
Parkville, VIC, Australia
East Melbourne, VIC 3002, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 02, 2025
Intervention Type: Drug
Study Phase: Phase 1
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: May 28, 2025
Intervention Type: Biological
Study Drug: EMB-06
Study Phase: Phase 1/Phase 2
An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma
An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma
Enrollment Status: No_longer_available
Publish Date: September 21, 2020
Intervention Type: Drug
View 4 Less Clinical Trials

11 Total Publications

Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.
Journal: Future oncology (London, England)
Published: July 17, 2025

Frequently Asked Questions about Miles H. Prince

Is Miles H. Prince a top-rated expert for T-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Miles H. Prince is classified as an Experienced expert for T-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Miles H. Prince participate in research or clinical trials?

Yes. Miles H. Prince has published 11 articles and abstracts on conditions like T-Cell Lymphoma. You can view a list of Miles H. Prince's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Prince's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile